Related Experiment Videos
[The Scandinavian Simvastatin Survival Study: the clinical consequences]
1Hospital Universitario de Aarhus, Amtssygehuset, Dinamarca.
Revista Espanola De Cardiologia
|January 1, 1995
Summary
Simvastatin significantly reduced coronary heart disease mortality by 42% and all-cause mortality by 30% in patients with existing coronary heart disease. This cholesterol-lowering therapy offers substantial benefits for patients with established heart disease.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Coronary heart disease (CHD) poses a significant global health burden.
- Effective cholesterol management is crucial for improving outcomes in CHD patients.
Purpose of the Study:
- To evaluate the efficacy of simvastatin in reducing mortality and major coronary events in patients with CHD.
- To analyze the impact of simvastatin across different baseline cholesterol levels.
Main Methods:
- The Scandinavian Simvastatin Survival Study (4S) randomized 4,444 patients with CHD to simvastatin or placebo.
- Patients received treatment for an average of 5.4 years.
- Analysis included major coronary events and mortality rates based on baseline cholesterol levels.
Main Results:
- Simvastatin reduced CHD mortality by 42% and all-cause mortality by 30% compared to placebo.
- Simvastatin significantly lowered the risk of major coronary events across all baseline cholesterol quartiles.
- The beneficial effects of simvastatin on CHD appeared after approximately one year of therapy.
Conclusions:
- Cholesterol-modifying interventions, like simvastatin, substantially improve outcomes for patients with established CHD.
- Assessment of plasma total cholesterol should be offered to all patients with documented ischemic heart disease.
- Patients with persistent high cholesterol (>200 mg/dL) after lifestyle changes should be considered for HMG-CoA reductase inhibitor therapy.